Clearside Biomedical, Inc.
CLSD
$3.70
-$0.39-9.54%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -44.63% | -55.47% | -79.77% | 248.39% | 365.02% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -44.63% | -55.47% | -79.77% | 248.39% | 365.02% |
| Cost of Revenue | 179.58% | 11.83% | -58.03% | -100.00% | -65.95% |
| Gross Profit | -48.94% | -58.42% | -80.75% | 366.28% | 514.65% |
| SG&A Expenses | -2.43% | 2.36% | -0.52% | -3.30% | -2.73% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -21.84% | -12.56% | -7.63% | 0.44% | 6.41% |
| Operating Income | 15.18% | -1.69% | -16.25% | 17.84% | 13.15% |
| Income Before Tax | 19.31% | 13.93% | -5.74% | 14.58% | 6.75% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 17.17% | 11.89% | -5.74% | 14.58% | 6.75% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 17.17% | 11.89% | -5.74% | 14.58% | 6.75% |
| EBIT | 15.18% | -1.69% | -16.25% | 17.84% | 13.15% |
| EBITDA | 16.08% | -0.89% | -15.66% | 18.21% | 13.24% |
| EPS Basic | 26.79% | 24.92% | 10.86% | 26.04% | 15.68% |
| Normalized Basic EPS | 28.66% | 26.63% | 10.86% | 26.04% | 15.68% |
| EPS Diluted | 26.79% | 24.92% | 10.86% | 26.37% | 16.07% |
| Normalized Diluted EPS | 28.66% | 26.63% | 10.86% | 26.04% | 15.68% |
| Average Basic Shares Outstanding | 13.53% | 18.11% | 19.40% | 14.89% | 10.50% |
| Average Diluted Shares Outstanding | 13.53% | 18.11% | 19.40% | 14.89% | 10.50% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |